The use of EZH2 inhibitors as well as other epigenetic inhibitors to sensitize drug resistance to clinically relevant treatment protocols may suggest epigenetic changes as possible underlying mechanism contributing to drug resistance in MM. Here, EZH2 is linked to Miyoshi myopathy.